Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethnicity Effect on DS-1040b PK/PD/Safety
NCT02647307Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS1040b in acute ischemic stroke (AIS) and pulmonary embolism (PE), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Plasma concentrations of DS-1040, Maximum Plasma Concentration and 3 more. Started Feb 2016; status: completed.
02
Drugs
DS1040b
03
Conditions
acute ischemic stroke (AIS)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT02647307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647307.